deletions | additions       diff --git a/Method.tex b/Method.tex  index 0cfa5c9..f2069cd 100644  --- a/Method.tex  +++ b/Method.tex 
...
***This subsection needs to be checked (+Eylea).***  ***should we not also mention the labelled IgG and BSA here?***  Ranibizumab and bevacizumab solutions were dialysed twice against phosphate buffered saline (PBS, pH 7.4) using D-Tube Midi Dialyzer units with a 6-8kD cut-off (Novagen). Subsequently, the purity of the dialysed proteins was checked by standard SDS-PAGE and confirmed to correspond to the manufacturer's purity values for the proteins. The proteins were then conjugated to the fluorophore Bis(2,2′-bipyridine)-4′-methyl-4-carboxybipyridine-ruthenium bis(hexafluorophosphate) (synonym, N-succinimidyl ester-Ru(bpy)2(mcbpy-O-Su-ester)(PF6)2)(Sigma-Aldrich) by using a N-succinimidyl ester-modified fluorophore (NHS-fluorophore) with a short linker (Invitrogen, F6130). Conjugation reactions were performed in PBS adjusted with 1M bicine buffer to pH 8.6 at 2mg/ml protein concentration in the dark at room temperature with the NHS-fluorophore being used at 2-fold molar excess. The reaction was stopped after 2.5h and conjugated proteins were separated from remaining free dye by size exclusion chromatography (Zeba(R) spin columns with a 7kD cut-off; Thermo Fisher). Using this method we generated ranibizumab conjugated to dye with a dye:protein ratio of 1.1:1 0.7:1  and bevacizumab with a dye:protein ratio of 1.3:1. Sodium azide was added to all fluorophore-conjugated drugs at a final concentration of 2.0mM to protect the protein solution from any microbial deterioration. \subsection{Tr-FAIM measurements}